BioDelivery Sciences to Report Second-Quarter 2018 Financial Results on August 9, 2018
24. Juli 2018 16:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 24, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it will report its second quarter 2018 financial results after the close...
BioDelivery Sciences to Present at the William Blair 2018 Growth Stock Conference
01. Juni 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading specialty pharmaceutical company in the field of pain management and addiction...
BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference
23. Mai 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board
22. Mai 2018 08:29 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 22, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced it has closed its previously announced $50 million registered direct offering...
BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business
17. Mai 2018 08:01 ET
|
BioDelivery Sciences International, Inc.
$50 Million Equity Financing Led By Broadfin Announced Separately Today Three New Independent Directors Selected by Broadfin Added To Board; Four Current Independent Directors Retiring Amends...
BioDelivery Sciences Announces Pricing of $50 Million Equity Financing
17. Mai 2018 08:01 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into definitive agreements with existing institutional and...
BioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate Update
10. Mai 2018 16:01 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® Net Revenues Increased 76% Over 1Q17Achieved Significant Prescription Growth Increase of 55% for BELBUCA in 1Q18 vs 1Q17 Achieved Company Total Net Revenue of $11.3 Million for 1Q18Addition...
BioDelivery Sciences Appoints Herm Cukier as Chief Executive Officer
07. Mai 2018 09:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 07, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
BioDelivery Sciences Confirms Receipt of Notice of Intent to Nominate Directors by Broadfin Capital
03. Mai 2018 09:01 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 03, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today issued the following statement with respect to its receipt of a notice from Broadfin...
BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2018 Financial Results on Thursday, May 10
30. April 2018 07:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...